News | Computed Tomography (CT) | March 27, 2018

Edwards Completes Enrollment in PARTNER 3 Low-Risk CT Sub-Study

Company also updates European launch for Sapien 3 Ultra System to late 2018

Edwards Completes Enrollment in PARTNER 3 Low-Risk CT Sub-Study
Valve Thrombosis Comparison

March 27, 2018 — Edwards Lifesciences Corp. announced that enrollment is complete in the computed tomography (CT) imaging sub-study within the PARTNER 3 trial of the Sapien 3 valve. This randomized sub-study is examining leaflet mobility of both the Sapien 3 valve and surgical heart valves in low-risk patients undergoing valve replacement for the treatment of severe aortic stenosis.

Enrollment in the PARTNER 3 main study of the Sapien 3 valve in low-risk patients was already complete. As previously indicated, Edwards continues to anticipate that data from the PARTNER 3 trial will be presented at the American College of Cardiology (ACC) 2019 annual meeting, and expects to receive U.S. Food and Drug Administration (FDA) approval for the indication late that year.

In addition, Edwards is studying the Sapien 3 Ultra System as part of a single-arm multi-center trial of up to 30 intermediate-risk patients. These data will be utilized to supplement the European regulatory filing for the Sapien 3 Ultra System. Edwards now expects that the European launch of the Sapien 3 Ultra system will occur later in 2018. This updated timing for the European launch does not change the company's sales guidance for 2018, and Edwards continues to expect the U.S. introduction of this system in late 2018.

For more information: www.edwards.com

 

Related Content

Iodine-based CT contrast ready for scanning with a Canon Aquilion One 320-slice CT system at Northwestern Medicine Central DuPage Hospital in the Chicago suburbs.
News | Radiology Imaging | January 22, 2020
January 22, 2020 — The risk of administering modern...
Virtual reality during chemotherapy has been shown to improve breast cancer patients’ quality of life during the most stressful treatments
News | Virtual and Augmented Reality | January 21, 2020
January 21, 2020 — Virtual reality during chemotherapy has been shown to improve...
This is a lung X-ray reviewed automatically by artificial intelligence (AI) to identify a collapsed lung (pneumothorax) in the color coded area. This AI app from Lunit is awaiting final FDA review and in planned to be integrated into several vendors' mobile digital radiography (DR) systems. Fujifilm showed this software integrated as a work-in-progress into its mobile X-ray system at RSNA 2019. GE Healthcare has its own version of this software for its mobile r=ray systems that gained FDA in 2019.   #RSNA #

This is a lung X-ray reviewed automatically by artificial intelligence (AI) to identify a collapsed lung (pneumothorax) in the color coded area. This AI app from Lunit is awaiting final FDA review and in planned to be integrated into several vendors' mobile digital radiography (DR) systems. Fujifilm showed this software integrated as a work-in-progress into its mobile X-ray system at RSNA 2019. GE Healthcare has its own version of this software for its mobile r=ray systems that gained FDA in 2019.

Feature | RSNA | January 20, 2020 | Dave Fornell, Editor
Here are images of some of the newest new medical imaging technologies displayed on the expo floor at the ...
Researchers at Karolinska Institutet in Sweden and Tampere University in Finland have developed a method based on artificial intelligence (AI) for histopathological diagnosis and grading of prostate cancer

From left: Peter Ström, Martin Eklund, Kimmo Kartasalo, Henrik Olsson och Lars Egevad, researchers at Karolinska Institutet in Sweden. Photo courtesy of Stefan Zimmerman

News | Prostate Cancer | January 20, 2020
January 20, 2020 — Researchers at Karolinska Institutet in Sweden and...
Videos | RSNA | January 13, 2020
ITN Editor Dave Fornell takes a tour of some of the most innovative new medical imaging technologies displayed on the
Professor Samer Ezziddin, M.D., from Saarland University/Saarland University Hospital.

Professor Samer Ezziddin, M.D., from Saarland University/Saarland University Hospital. Image courtesy of Saarland University/Thorsten Mohr

 

News | Prostate Cancer | January 13, 2020
January 13, 2020 — When a non-scientist tries to imagine a scientist, the image that often arises is one of a somewha
The study found that DBN laws helped some women understand they had increased breast density, but not that breast density is associated with a higher risk of breast cancer or that dense breasts limit the ability of mammograms to detect cancer
News | Breast Density | January 09, 2020
January 9, 2020 — A new study suggests that state-mandated notifications on...